Clinical trial · Interventional
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
Clinical Investigation of Chimeric Costimulatory Converting Receptor(CCCR)-Modified NK92 Cells in Previously Treated Advanced Non-small Cell Lung Carcinoma
NCT03656705CI-TRIAL-00067997completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this clinical investigation is to evaluate the safety and effects of CCCR-modified NK92(CCCR-NK92)infusions in previously treated advanced non-small cell lung carcinoma(NSCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CCCR-NK92 cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CCCR-NK92 cells immunotherapy
- description
- Preparation of CCCR-NK92 cells suspended in a saline and plasma solution.
- interventionNames
- Biological: CCCR-NK92 cells
Primary outcomes (2)
- measure
- Number of participants with adverse events evaluated with CTCAE,version 4.0
- timeFrame
- 3 months
- description
- Safety evaluation
- measure
- Objective Response Rate
- timeFrame
- up to one year
- description
- Non-small cell lung carcinoma to CCCR-NK92 cell infusions
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * 1.Male and female subjects with non-small cell lung carcinoma in patients with no available curative treatment options who have limited prognosis(≧3 months)with currently available therapies will be enrolled. * 2.The last cytotoxic drug, radiotherapy or surgery≧4 weeks. * 3.HB≧90g/L, ANC≧1.5×10e9/L, PLT≧80×10e9/L, TBIL≦1.5×upper limit of nomal, ALT/AST≦2.5×upper limit of nomal, ALT/AST≦5×upper limit of nomal if have liver metastasis, Cr≦1.5×upper limit of nomal or CCr≧60ml/min. Exclusion Criteria: * 1.Pregnancy or breastfeeding. * 2.Known HIV, HBV or HCV infection. * 3.Active antoimmune disease. * 4.History of severe immediate hypersensitivity to any of the biological products including penicillin. * 5.Severe psychiatric disorder which might interfere with the study treatment or examination. * 6.Chronic heart failure NYHA≧III. * 7.Simultaneous participation in another clinical trial within 4 weeks.
References
Publications (0)
Data not yet available
No reference posted for this study.